Xi'an Xintong Pharmaceutical Research Co.,Ltd.

9 clinical trials · Sponsor

Record	Firm	Date
A Randomized, Double-blind, Single-center Phase I/IIa Study of XTYW007 Tablets in Subjects. (NCT07407634)	Xi'an Xintong Pharmaceutical Research Co.,Ltd.	2026-03-25
Efficacy and Safety of Pracytarabine Versus Regorafenib in the Treatment of Patients With Hepatocellular Carcinoma (NCT07300488)	Xi'an Xintong Pharmaceutical Research Co.,Ltd.	2025-09-01
A Phase II/III of Hepenofovir Fumarate Tablets (HTS) for Chronic Hepatitis B (NCT07203118)	Xi'an Xintong Pharmaceutical Research Co.,Ltd.	2025-07-01
Safety, Tolerability Phase Ia Study of XT1061 in Single and Multiple Doses in Healthy Subjects (NCT06280534)	Xi'an Xintong Pharmaceutical Research Co.,Ltd.	2023-07-18
A Phase Ic/IIb Study to Evaluate the Efficacy，Safety and Pharmacokinetics of HST in Patients With CHB (NCT06122454)	Xi'an Xintong Pharmaceutical Research Co.,Ltd.	2022-11-10
Treatment of MB07133 Plus Sintilimab in Patients With Hepatocellular Carcinoma (NCT06141109)	Xi'an Xintong Pharmaceutical Research Co.,Ltd.	2022-01-18
A Study to Investigate the Safety, Tolerability, Pharmacokinetics of Single and Multiple Doses of Hepenofovir Fumarate Tablets in Healthy Volunteers. (NCT04277897)	Xi'an Xintong Pharmaceutical Research Co.,Ltd.	2020-03-15
MB07133 for the Treatment of Patients With Unresectable Hepatocellular Carcinoma (NCT06141096)	Xi'an Xintong Pharmaceutical Research Co.,Ltd.	2020-01-17

Every clearance here is in the API, with alerts when new ones post.